Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has, of course, returned. This leaves us with little choice but to fire up the coffee kettle and quaff a few cups of stimulation. Our choice today is coconut, for those tracking this sort of behavior. Feel free to join us. Meanwhile, here are some tidbits to help you along as the journey begins. Hope you have a smashing day and please do keep in touch …

AbbVie (ABBV) was reprimanded by the Food and Drug Administration for sloppy procedures when reviewing complaints of deaths that were reported in connection with three of its medicines, STAT reports. Following an inspection at an Illinois facility late last year, FDA examiners found the company failed to “thoroughly investigate” complaints over certain syringe kits for one medication that were associated with deaths, and also neglected to properly include historical complaint information for sorting through new reports that cited deaths for at least two other products.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy